Stock GHDN BRAINSTORM CELL THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Brainstorm Cell Therapeutics Inc. Deutsche Boerse AG

Equities

GHDN

US10501E2019

Market Closed - Deutsche Boerse AG
Other stock markets
 08:24:09 28/06/2024 BST 		5-day change 1st Jan Change
0.322 EUR -9.30% Intraday chart for Brainstorm Cell Therapeutics Inc. -8.26% +40.00%
06-27 Brainstorm Cell Therapeutics Prices Registered Direct Offering, Concurrent Private Placement MT
06-26 Brainstorm Cell Therapeutics Inc. Reaches Alignment with Fda on Cmc Aspects of Phase 3B Nurown®? Clinical Trial CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Brainstorm Cell Therapeutics Prices Registered Direct Offering, Concurrent Private Placement
MT
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
PR
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn Clinical Trial
AQ
Brainstorm Cell Therapeutics Inc. Reaches Alignment with Fda on Cmc Aspects of Phase 3B Nurown®? Clinical Trial
CI
Brainstorm Cell Therapeutics Announces Appointment of Haro Hartounian as EVP and COO
CI
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
PR
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
PR
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit from Longer-Term Treatment with NurOwn
CI
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
PR
Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024
CI
Brainstorm Cell Therapeutics Inc. Announces Management Changes
CI
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
PR
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment for Phase 3b Trial in ALS
AQ
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
PR
Brainstorm Cell Therapeutics Says FDA Agrees on Design of Phase 3B ALS Trial
MT
Transcript : Brainstorm Cell Therapeutics Inc. - Special Call
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
PR
BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALS
CI
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCLI Stock
  4. GHDN Stock
  5. News Brainstorm Cell Therapeutics Inc.